<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Valeant Pharmaceuticals International</title>
	<atom:link href="http://www.stockbloghub.com/tag/valeant-pharmaceuticals-international/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ARQL) Company News for January 18, 2012 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416</link>
		<comments>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416#comments</comments>
		<pubDate>Wed, 18 Jan 2012 20:42:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ARQL]]></category>
		<category><![CDATA[ArQule Inc]]></category>
		<category><![CDATA[Blackbaud Inc]]></category>
		<category><![CDATA[BLKB]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Venoco Inc]]></category>
		<category><![CDATA[VQ]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90416</guid>
		<description><![CDATA[•    Bio technology company ArQule Inc.’s (NASDAQ:ARQL) share prices gained 11.91% to close at $6.67 after the company&#8217;s experimental treatment for liver cancer reported a positive outcome in its Phase II trial •    Share prices of discount carrier Sprint Airlines Inc. (NASDAQ:SAVE) declined 5.53% after the company announced plans to sell 11 million shares in a secondary offering •    Global provider of software Blackbaud Inc. (NASDAQ:BLKB) will buy fund raising software maker Convio Inc. (NASDAQ:CNVO) for $16 per share. Following the news, shares of Convio rocketed up 48% to close at $15.89 a share •    ISTA Pharmaceuticals Inc.’s shares (NASDAQ:ISTA) gained 13.07% after Valeant Pharmaceuticals International Inc. (NYSE:VRX) increased its hostile-takeover bid for ISTA to $7.50 a share •    Shares of natural gas firm Venoco Inc. (NYSE:VQ) surged 29.91% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ADBE) Company News for December 19, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/12/19/adbe-company-news-for-december-19-2011-corporate-summary/88857</link>
		<comments>http://www.stockbloghub.com/2011/12/19/adbe-company-news-for-december-19-2011-corporate-summary/88857#comments</comments>
		<pubDate>Mon, 19 Dec 2011 19:51:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Application Software]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ADBE]]></category>
		<category><![CDATA[Adobe Systems Inc.]]></category>
		<category><![CDATA[Cablevision Systems Corporation]]></category>
		<category><![CDATA[CVC]]></category>
		<category><![CDATA[Darden Restaurants Inc.]]></category>
		<category><![CDATA[DRI]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88857</guid>
		<description><![CDATA[•    Zynga, Inc. (NASDAQ:ZNGA) made its debut on the Nasdaq and dropped 5.0% to $9.50. The company’s initial public offering was priced at $10.00 per share •    Shares of Adobe Systems Inc. (NASDAQ:ADBE) jumped 6.6% a day after reporting fully diluted pro forma earnings per share of $0.55, topping the Zacks Consensus Estimate of $0.50 per share •    United Rentals, Inc.’s (NYSE:URI) $1.9 billion acquisition bid for RSC Holdings, Inc. (NYSE:RRR) helped RSC’s shares gain a whopping 57.9% •    Shares of Cablevision Systems Corporation (NYSE:CVC) plummeted 8.5% after the company said that its chief operating officer has planned to vacate office this month •    Valeant Pharmaceuticals International, Inc.’s (NYSE:VRX) acquisition offer of ISTA Pharmaceuticals Inc. (NASDAQ:ISTA) for $6.50 per share took the latter’s stocks up by 71.7% •    Darden Restaurants, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/19/adbe-company-news-for-december-19-2011-corporate-summary/88857/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGII) Company News for August 9, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/09/agii-company-news-for-august-9-2011-corporate-summary/80946</link>
		<comments>http://www.stockbloghub.com/2011/08/09/agii-company-news-for-august-9-2011-corporate-summary/80946#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:08:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property & Casualty Insurance]]></category>
		<category><![CDATA[AGII]]></category>
		<category><![CDATA[AIG]]></category>
		<category><![CDATA[American International Group Inc]]></category>
		<category><![CDATA[Argo Group International Holdings Limited]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Berkshire Hathaway]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[BRKA]]></category>
		<category><![CDATA[BRKB]]></category>
		<category><![CDATA[DG FastChannel Inc]]></category>
		<category><![CDATA[DGIT]]></category>
		<category><![CDATA[Dollar Thrifty Automotive Group Inc]]></category>
		<category><![CDATA[DTG]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JB Hunt Transport Services Inc]]></category>
		<category><![CDATA[JBHT]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[Transatlantic Holdings Inc.]]></category>
		<category><![CDATA[TRH]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80946</guid>
		<description><![CDATA[•    Share prices of America&#8217;s biggest bank, Bank of America Corp. (NYSE:BAC) fell 20.32% after a report in the New York Times said that American International Group, Inc. (NYSE:AIG) has filed a suit against the bank to recover more than $10 billion in losses due to mortgage-backed securities •    Car rental company Dollar Thrifty Automotive Group, Inc.&#8217;s (NYSE:DTG) shares declined by 12.75% to close at $58.79 after the company posted second quarter earnings results that came in below expectations •    Share prices of DG FastChannel Inc. (NASDAQ:DGIT) fell 24.95% after the company, which is primarily engaged in advertising and distribution, reported a fall in quarterly revenue results that came in below estimates •    Telecom-software maker BroadSoft Inc.’s  (NASDAQ:BSFT) share prices rose 9.70% after the company&#8217;s forecasted earnings for fiscal 2011 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/agii-company-news-for-august-9-2011-corporate-summary/80946/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals International Beats Expectations &#8211; Ups View</title>
		<link>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862</link>
		<comments>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862#comments</comments>
		<pubDate>Mon, 08 Aug 2011 17:31:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Cogdell Spencer Inc.]]></category>
		<category><![CDATA[CSA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80862</guid>
		<description><![CDATA[Valeant Pharmaceuticals International’s (VRX) second quarter 2011 earnings of 68 cents per share (excluding special items but including stock based compensation expense) beat the Zacks Consensus Estimate by 3 cents and the year-ago earnings by 8 cents per share. Bottom-line growth was driven by improved revenues. Adjusted diluted earnings, however, included an extraordinary gain of 6 cents from the sale of investment in Cephalon Inc. (CEPH). Revenues for the quarter were $609.4 million, marginally above the Zacks Consensus Estimate of $609 million and way ahead of the prior-year figure of $238.8 million. However, revenue included a one-time milestone payment of $40 million received from GlaxoSmithkline (GSK) related to the European launch of Trobalt (known as Potiga in the US). The improvement in revenues was primarily due to the September 2010 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy&#8217;s Laboratories Continues to Grow</title>
		<link>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172</link>
		<comments>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172#comments</comments>
		<pubDate>Fri, 03 Jun 2011 14:11:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74172</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) reported fiscal 2011 earnings per American Depositary Share (ADS) of $1.50 compared with 10 cents per ADS posted in fiscal 2010. Higher revenues and lower operating expenses helped boost earnings. Year at a Glance The company reported revenues of $1.7 billion during the fiscal year, reflecting a year-over-year increase of 6%. Dr. Reddy’s reports revenues under two segments – Global Generics and Pharmaceutical Services &#38; Active Ingredients (PSAI). Revenues at the Global Generics segment increased 10% to $1.2 billion. However, PSAI revenues declined 4% to $441 million during the year. While generics revenues increased 18% in North America, 19% in Russia and other CIS (Commonwealth of Independent States) markets, and 15% in India, they deteriorated 13% in Europe. In the European market, Germany was worst hit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DSW) Company News for May 25, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/25/dsw-company-news-for-may-25-2011-corporate-summary/74883</link>
		<comments>http://www.stockbloghub.com/2011/05/25/dsw-company-news-for-may-25-2011-corporate-summary/74883#comments</comments>
		<pubDate>Wed, 25 May 2011 15:53:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Apparel Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AutoZone Inc.]]></category>
		<category><![CDATA[AZO]]></category>
		<category><![CDATA[DSW]]></category>
		<category><![CDATA[DSW Inc.]]></category>
		<category><![CDATA[El Paso Corporation]]></category>
		<category><![CDATA[EP]]></category>
		<category><![CDATA[FPIC]]></category>
		<category><![CDATA[FPIC Insurance Group Inc.]]></category>
		<category><![CDATA[Gentiva Health Services Inc.]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[GTIV]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Thomson S.A.]]></category>
		<category><![CDATA[TMS]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74883</guid>
		<description><![CDATA[•    Shares of Yandex NV (NASDAQ:YNDX) gained more than 55% to close at $38.84 in its opening trading day at the American exchange. Yandex is a Russian internet search company and its IPO was the biggest in the Internet sector after Google (NASDAQ:GOOG) •    Automotive-parts retailer AutoZone, Inc.’s (NYSE:AZO) shares surged 5.97% after the company reported third-quarter results that came in above analysts estimates and the Street’s expectations •    Shoe retailer DSW Inc. (NYSE:DSW) raised its profit forecast for the fiscal year 2012. As a result of this development, the company’s shares gained 16.86% to close at $50.47 •    Coverage on shares of Motorola Solutions Inc (NYSE:MSI) was initiated by Goldman Sachs (NYSE:GS) with a &#8220;Buy&#8221; rating and a target price of $57 •    Shares of Gentiva Health Services, Inc. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/25/dsw-company-news-for-may-25-2011-corporate-summary/74883/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues</title>
		<link>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944</link>
		<comments>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944#comments</comments>
		<pubDate>Wed, 18 May 2011 15:22:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73944</guid>
		<description><![CDATA[Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 10 cents per share. Revenues for the quarter increased to $565 million, well above the Zacks Consensus Estimate of $517 million and the prior-year quarter’s revenue of $219.6 million. However, revenue included a one-time alliance and royalty revenue of $36 million related to the March 2011 out-licensing of product rights to Cloderm cream, a mid-potency steroid to Dr. Reddy&#8217;s Laboratories (RDY). Excluding the one-time payment, revenue was $529 million, which was still above both the Zacks Consensus Estimate and the prior-year revenue. Organically (excluding the impact of one-time revenues, acquisitions and foreign exchange), revenues grew 7% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon First Quarter 2011 Earnings Miss Expectations</title>
		<link>http://www.stockbloghub.com/2011/05/05/ceph-cephalon-first-quarter-2011-earnings-miss-expectations/73295</link>
		<comments>http://www.stockbloghub.com/2011/05/05/ceph-cephalon-first-quarter-2011-earnings-miss-expectations/73295#comments</comments>
		<pubDate>Thu, 05 May 2011 15:46:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73295</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) delivered first quarter earnings of $1.98 per share, several cents below the Zacks Consensus Estimate of $2.04 but 12.5% above the year-ago earnings of $1.76. First quarter revenues, which increased 24.9% to $745.1 million, missed the Zacks Consensus Estimate of $752 million by a wide margin. First quarter results were within the guidance range provided by the company. Cephalon had guided towards adjusted net income of $144 &#8211; $159 million on sales of $725 &#8211; $755 million. The Quarter in Detail First quarter revenues consisted of $736 million in product sales (up 27.6%) and $9.1 million in other revenues. All segments performed well during the quarter. The central nervous system (CNS) and oncology franchises posted sales of $334.7 million (up 7%) and $149.1 million (up 35%), respectively. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/ceph-cephalon-first-quarter-2011-earnings-miss-expectations/73295/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Announces Aquisition of Cephalon</title>
		<link>http://www.stockbloghub.com/2011/05/03/teva-teva-pharmaceutical-industries-announces-aquisition-of-cephalon/73024</link>
		<comments>http://www.stockbloghub.com/2011/05/03/teva-teva-pharmaceutical-industries-announces-aquisition-of-cephalon/73024#comments</comments>
		<pubDate>Tue, 03 May 2011 18:10:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73024</guid>
		<description><![CDATA[Yet another acquisition deal was announced in the pharma sector with generic player, Teva Pharmaceutical Industries Ltd. (TEVA) entering into a definitive agreement with Cephalon, Inc. (CEPH). Teva intends to acquire Cephalon for $81.50 per share in cash or $6.8 billion. Teva Tops Valeant Bid Cephalon has been in the news over the past few weeks with Valeant Pharmaceuticals (VRX) expressing an interest in acquiring the company. Valeant had initially approached Cephalon in late March with a $73 bid. However, Cephalon rejected the offer. Teva’s offer price tops Valeant’s offer and represents a 39% premium to Cephalon’s stock price before Valeant’s unsolicited proposal was announced. Deal in line with Long-Term Strategy The Cephalon deal is in line with Teva’s long-term strategy of expanding and strengthening its branded and specialty pharma ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/teva-teva-pharmaceutical-industries-announces-aquisition-of-cephalon/73024/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline and Valeant Pharmaceuticals Respond to CRL From FDA</title>
		<link>http://www.stockbloghub.com/2011/04/26/gsk-glaxosmithkline-and-valeant-pharmaceuticals-respond-to-crl-from-fda/72377</link>
		<comments>http://www.stockbloghub.com/2011/04/26/gsk-glaxosmithkline-and-valeant-pharmaceuticals-respond-to-crl-from-fda/72377#comments</comments>
		<pubDate>Tue, 26 Apr 2011 15:34:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72377</guid>
		<description><![CDATA[GlaxoSmithKline (GSK) and Valeant Pharmaceuticals (VRX) recently submitted a response to the Complete Response Letter (CRL) received from the US Food and Drug Administration (FDA) for their epilepsy candidate, ezogabine. The CRL, which was issued in Nov 2010, was for non-clinical reasons. We note that earlier, in August 2010, Glaxo and Valeant had received a positive recommendation from an FDA advisory panel regarding ezogabine. The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee had reviewed the safety and efficacy of the drug and voted unanimously in favor of ezogabine’s efficacy for the treatment of partial-onset seizures in adults where other treatments failed. However, later during the month, the FDA extended the review date for the candidate by three months. Approved in the EU Meanwhile, Glaxo and Valeant announced that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/26/gsk-glaxosmithkline-and-valeant-pharmaceuticals-respond-to-crl-from-fda/72377/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BRCM) Company News for April 07, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/07/brcm-company-news-for-april-07-2011-corporate-summary/70919</link>
		<comments>http://www.stockbloghub.com/2011/04/07/brcm-company-news-for-april-07-2011-corporate-summary/70919#comments</comments>
		<pubDate>Thu, 07 Apr 2011 17:22:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor - Integrated Circuits]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[BRCM]]></category>
		<category><![CDATA[Broadcom Corporation]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[G]]></category>
		<category><![CDATA[Genpact Limited]]></category>
		<category><![CDATA[LGF]]></category>
		<category><![CDATA[Lions Gate Entertainment Corporation]]></category>
		<category><![CDATA[MON]]></category>
		<category><![CDATA[Monsanto Company]]></category>
		<category><![CDATA[Netflix Inc.]]></category>
		<category><![CDATA[NFLX]]></category>
		<category><![CDATA[Skyworks Solutions Inc.]]></category>
		<category><![CDATA[SWKS]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[WD-40 Company]]></category>
		<category><![CDATA[WDFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70919</guid>
		<description><![CDATA[• New York Times reported that Cephalon, Inc. (NASDAQ:CEPH) rejected Valeant Pharmaceuticals&#8217; (NYSE:VRX) unsolicited $5.7 billion takeover bid, citing the offer was too low and opportunistic • Monsanto Company (NYSE:MON) reported a Q2 EPS of $1.88 beating the Zacks Consensus Estimate of $1.08 per share • WD-40 Company (NASDAQ:WDFC) reported Q2 EPS of $0.53, lower than the Zacks Consensus Estimate of $0.60 per share. Revenues for the quarter fell 2% year-over-year to $79.2 million, missing the Zacks Consensus Estimate of $90.0 million • Genpact Ltd (NYSE:G) has agreed to acquire global IT consulting firm Headstrong Corp for $550 million. The deal is expected to close in May, and Genpact expects the company to add to its earnings for the year • According to reports, Citigroup (NYSE:C) is looking to expand its commodity investment-product team over ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/brcm-company-news-for-april-07-2011-corporate-summary/70919/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EIA) Stock Market News for March 31, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/03/31/eia-stock-market-news-for-march-31-2011-market-news/70353</link>
		<comments>http://www.stockbloghub.com/2011/03/31/eia-stock-market-news-for-march-31-2011-market-news/70353#comments</comments>
		<pubDate>Thu, 31 Mar 2011 19:14:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Closed-End Fund - Debt]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Chesapeake Energy Corporation]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CHK]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DFS]]></category>
		<category><![CDATA[Discover Financial Services]]></category>
		<category><![CDATA[Eaton Vance Insured California Municipal Bond Fund]]></category>
		<category><![CDATA[EIA]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[MA]]></category>
		<category><![CDATA[Marathon Oil Corporation]]></category>
		<category><![CDATA[Mastercard Incorporated]]></category>
		<category><![CDATA[MRO]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Tesoro Corporation]]></category>
		<category><![CDATA[TSO]]></category>
		<category><![CDATA[V]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Valero Energy Corporation]]></category>
		<category><![CDATA[Visa Inc]]></category>
		<category><![CDATA[VLO]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70353</guid>
		<description><![CDATA[Markets enjoyed an extended stay in the green following reports of new jobs being created in the private-sector. Domestic data was strong enough to counter any concerns arising from the euro-zone debt woes, Libyan unrest and the Japan nuclear crisis. The Dow inched closer to the levels of February 18, which was the highest close since June 5, 2008. The Dow Jones Industrial Average (DJIA) is en route to its best quarter performance and is within striking distance of reaching its highest levels for 2011. The gains come amidst a host of global tensions and it likely reflects the strength of the domestic economy, which has helped the indices recover from the damages it suffered. The Dow gained 0.6% to close at 12,350.61. The Standard &#38; Poor 500 (S&#38;P 500) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/31/eia-stock-market-news-for-march-31-2011-market-news/70353/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACXM) Company News for March 31, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/03/31/acxm-company-news-for-march-31-2011-corporate-summary/70355</link>
		<comments>http://www.stockbloghub.com/2011/03/31/acxm-company-news-for-march-31-2011-corporate-summary/70355#comments</comments>
		<pubDate>Thu, 31 Mar 2011 19:12:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Acxiom Corporation]]></category>
		<category><![CDATA[ACXM]]></category>
		<category><![CDATA[ALGN]]></category>
		<category><![CDATA[Align Technology Inc]]></category>
		<category><![CDATA[BBY]]></category>
		<category><![CDATA[Best Buy Company Inc]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BRKR]]></category>
		<category><![CDATA[Bruker Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CONN]]></category>
		<category><![CDATA[Conns Inc.]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GEOI]]></category>
		<category><![CDATA[GeoResources Inc]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70355</guid>
		<description><![CDATA[• According to a report from Bloomberg, Valeant Pharmaceuticals (NYSE:VRX) made a hostile bid to acquire Cephalon (NASDAQ:CEPH) for about $73 a share in cash or about $5.7 billion, after earlier bids were rejected • Standard &#38; Poor’s said the world’s biggest asset manager BlackRock Inc (NYSE:BLK) would replace Genzyme Corp. (NASDAQ:GENZ)  in the S&#38;P 500 index  after Friday’s close • Wells Fargo Securities initiated coverage on exploration company GeoResources Inc. (NASDAQ:GEOI)  with an “Outperform” rating • Chinese internet company Qihoo 360 Technology Company (NYSE:QIHU) made its debut on the New York Stock Exchange with a bang with share prices rising 134.48% to close at $34.00 • Data-services provider Acxiom Corp (NASDAQ:ACXM) announced that its CEO had resigned, effective two days ago, and that its CFO plans to step down • Align Technologies (NASDAQ:ALGN) said it ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/31/acxm-company-news-for-march-31-2011-corporate-summary/70355/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals International&#8217;s Sales Benefit Post Merger</title>
		<link>http://www.stockbloghub.com/2011/03/07/vrx-valeant-pharmaceuticals-internationals-sales-benefit-post-merger/67808</link>
		<comments>http://www.stockbloghub.com/2011/03/07/vrx-valeant-pharmaceuticals-internationals-sales-benefit-post-merger/67808#comments</comments>
		<pubDate>Mon, 07 Mar 2011 18:03:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67808</guid>
		<description><![CDATA[Valeant Pharmaceuticals International‘s (VRX) fourth quarter 2010 earnings of 46 cents per share missed the Zacks Consensus Estimate by a cent and was 45.2% below the year-ago earnings of 84 cents per share. Revenues for the quarter increased 102.7% year over year to $514.6 million, in line with the Zacks Consensus. While fourth quarter earnings were within the company’s guidance range of 44 cents to 48 cents per share, revenues were slightly above the guidance of $500 million. Earnings in 2010 declined 19.3% year over year to $1.97 per share, nevertheless beating the Zacks Consensus Estimate of $1.34. Revenues, which saw an increase of 44.0% to $1.18 billion, beat the Zacks Consensus Estimate of $1.15 billion. The increase in revenues was primarily due to the September 2010 merger of Valeant ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/07/vrx-valeant-pharmaceuticals-internationals-sales-benefit-post-merger/67808/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACHN) Achillion Pharmaceuticals&#8217; Pipeline Makes Progress</title>
		<link>http://www.stockbloghub.com/2010/10/03/achn-achillion-pharmaceuticals-pipeline-makes-progress/53720</link>
		<comments>http://www.stockbloghub.com/2010/10/03/achn-achillion-pharmaceuticals-pipeline-makes-progress/53720#comments</comments>
		<pubDate>Mon, 04 Oct 2010 05:11:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Achillion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ACHN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53720</guid>
		<description><![CDATA[Recently, Achillion Pharmaceuticals, Inc. (ACHN) announced that it has started dosing patients in a randomized, double-blind mid-stage study (n~120) that will evaluate pipeline candidate ACH-1625. The candidate is being developed to treat patients infected with hepatitis C virus (HCV). The placebo-controlled phase IIa study, to be conducted in the United States and Europe, will evaluate the safety, tolerability and antiviral activity of the HCV candidate as a combination therapy. Specifically, ACH-1625 (an oral candidate) will be evaluated in conjunction with pegylated interferon alfa-2a and ribavirin after 4 and 12 weeks of dosing in patients infected with chronic HCV genotype 1. While results from the 4 week study are expected in the first quarter of 2011, the 12 week study results are anticipated by the end of 2011. ACH-1625, a HCV ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/03/achn-achillion-pharmaceuticals-pipeline-makes-progress/53720/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Biovail and Valeant Pharmaceuticals International to Merge</title>
		<link>http://www.stockbloghub.com/2010/06/28/vrx-biovail-and-valeant-pharmaceuticals-international-to-merge/41157</link>
		<comments>http://www.stockbloghub.com/2010/06/28/vrx-biovail-and-valeant-pharmaceuticals-international-to-merge/41157#comments</comments>
		<pubDate>Tue, 29 Jun 2010 04:28:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Biovail Corporation]]></category>
		<category><![CDATA[BVF]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JEF]]></category>
		<category><![CDATA[Jefferies Group Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=41157</guid>
		<description><![CDATA[Recently, Valeant Pharmaceuticals International (VRX) and Canadian drugmaker Biovail Corp. (BVF) announced that they have agreed to merge, thereby creating a new company that will operate under the name Valeant Pharmaceuticals International, Inc.  The transaction has been approved by the Boards of both companies. The transaction, which will create a giant specialty pharmaceuticals company, is expected to close by year-end. The companies have taken a loan of $2.8 billion from Goldman Sachs (GS), Morgan Stanley (MS), and Jefferies and Co., a division of Jefferies Group Inc. (JEF), to finance the deal. The merged entity is expected to pay a $1.00 per share special dividend by the end of 2010. The deal, valued at approximately $3.3 billion, entitles the shareholders of Valeant to a one-time special cash dividend of $16.77 per share ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/28/vrx-biovail-and-valeant-pharmaceuticals-international-to-merge/41157/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals International Drug Accepted by FDA</title>
		<link>http://www.stockbloghub.com/2010/01/04/vrx-valeant-pharmaceuticals-international-drug-accepted-by-fda/24088</link>
		<comments>http://www.stockbloghub.com/2010/01/04/vrx-valeant-pharmaceuticals-international-drug-accepted-by-fda/24088#comments</comments>
		<pubDate>Mon, 04 Jan 2010 17:54:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24088</guid>
		<description><![CDATA[Recently, Valeant Pharmaceuticals International (VRX) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for marketing approval for its drug candidate retigabine. Retigabine is a neuronal potassium channel opener indicated for treating adult epilepsy patients with partial-onset seizures. Valeant has high hopes for its seizure drug, which is co-developed with GlaxoSmithKline PLC (GSK). The agreement pertains to the development and marketing of the drug in the U.S., Canada, Puerto Rico, Australia and New Zealand. Glaxo has exclusive rights pertaining to retigabine elsewhere. Retigabine displayed encouraging results in late-stage studies reducing seizure rates compared to a placebo. The most common adverse effects are dizziness, fatigue, vertigo, tremor, abnormal coordination, diplopia, disturbance in attention, asthenia and blurring of vision. The thrice-a-day pill could get the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/04/vrx-valeant-pharmaceuticals-international-drug-accepted-by-fda/24088/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNTS) Top Performer for Wed: Santarus- Zacks #1 Rank Top Performers</title>
		<link>http://www.stockbloghub.com/2009/11/11/snts-top-performer-for-wed-santarus-zacks-1-rank-top-performers/20261</link>
		<comments>http://www.stockbloghub.com/2009/11/11/snts-top-performer-for-wed-santarus-zacks-1-rank-top-performers/20261#comments</comments>
		<pubDate>Wed, 11 Nov 2009 20:43:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Santarus Inc]]></category>
		<category><![CDATA[SNTS]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20261</guid>
		<description><![CDATA[Shares of Santarus, Inc. (SNTS) have moved north of 7.5% this morning, which has made this specialty biopharmaceutical company a top-performing Zacks #1 Rank stock. Last week, the company announced third-quarter results that included another positive earnings per share surprise, as well as a raised 2009 guidance. Earnings estimates have responded in kind by gaining in the past 7 trading days. Volume on Wednesday is approximately 317,000 shares, which is above the daily average of nearly 250,000. Santarus focuses on acquiring, developing and commercializing proprietary products for the prevention and treatment of gastrointestinal diseases and disorders. Its efforts are focused on ZEGERID® for the treatment of certain upper GI diseases and disorders, and GLUMETZA® to improve glycemic control in adults with type 2 diabetes. SNTS is 1 of 4 companies ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/snts-top-performer-for-wed-santarus-zacks-1-rank-top-performers/20261/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANDS) Anadys Begins Mid-Stage Trial</title>
		<link>http://www.stockbloghub.com/2009/09/11/ands-anadys-begins-mid-stage-trial/14986</link>
		<comments>http://www.stockbloghub.com/2009/09/11/ands-anadys-begins-mid-stage-trial/14986#comments</comments>
		<pubDate>Fri, 11 Sep 2009 23:12:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Anadys Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANDS]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14986</guid>
		<description><![CDATA[Yesterday, Anadys Pharmaceuticals Inc. (ANDS) started a 12-week phase II trial of its ANA598 for hepatitis C patients. ANA 598 will be evaluated in combination with interferon-alpha and ribavirin (current standard of care) in the mid-stage study. Data from the trial is expected to be released at the end of this year and in the first two quarters of 2010. A total of 90 patients are planned to be enrolled in the study, with 30 patients receiving ANA598 and 15 receiving placebo at each dose level. The study would test 200 mg and 400 mg doses of the drug. In order to maximize early viral suppression, each patient would receive two 800 mg doses on the first day. The study would be conducted at various sites in the U.S. Chronic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/11/ands-anadys-begins-mid-stage-trial/14986/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

